全文获取类型
收费全文 | 6370篇 |
免费 | 398篇 |
国内免费 | 286篇 |
专业分类
耳鼻咽喉 | 21篇 |
儿科学 | 52篇 |
妇产科学 | 98篇 |
基础医学 | 1220篇 |
口腔科学 | 93篇 |
临床医学 | 446篇 |
内科学 | 945篇 |
皮肤病学 | 75篇 |
神经病学 | 828篇 |
特种医学 | 99篇 |
外科学 | 384篇 |
综合类 | 900篇 |
预防医学 | 300篇 |
眼科学 | 45篇 |
药学 | 533篇 |
中国医学 | 386篇 |
肿瘤学 | 629篇 |
出版年
2024年 | 3篇 |
2023年 | 100篇 |
2022年 | 126篇 |
2021年 | 154篇 |
2020年 | 95篇 |
2019年 | 111篇 |
2018年 | 102篇 |
2017年 | 128篇 |
2016年 | 138篇 |
2015年 | 135篇 |
2014年 | 232篇 |
2013年 | 288篇 |
2012年 | 290篇 |
2011年 | 343篇 |
2010年 | 351篇 |
2009年 | 344篇 |
2008年 | 396篇 |
2007年 | 393篇 |
2006年 | 374篇 |
2005年 | 327篇 |
2004年 | 316篇 |
2003年 | 300篇 |
2002年 | 264篇 |
2001年 | 262篇 |
2000年 | 211篇 |
1999年 | 179篇 |
1998年 | 156篇 |
1997年 | 134篇 |
1996年 | 120篇 |
1995年 | 140篇 |
1994年 | 118篇 |
1993年 | 83篇 |
1992年 | 73篇 |
1991年 | 55篇 |
1990年 | 42篇 |
1989年 | 35篇 |
1988年 | 20篇 |
1987年 | 16篇 |
1986年 | 14篇 |
1985年 | 26篇 |
1984年 | 17篇 |
1983年 | 3篇 |
1982年 | 8篇 |
1981年 | 11篇 |
1980年 | 6篇 |
1979年 | 6篇 |
1978年 | 6篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
排序方式: 共有7054条查询结果,搜索用时 203 毫秒
21.
Orazio Palmieri Tommaso Mazza Gabrio Bassotti Antonio Merla Salvatore Tolone Tommaso Biagini Antonello Cuttitta Fabrizio Bossa Giuseppina Martino Tiziana Latiano Giuseppe Corritore Domenica Gioffreda Orazio Palumbo Massimo Carella Anna Panza Angelo Andriulli Anna Latiano 《Neurogastroenterology and motility》2020,32(3)
22.
《Vaccine》2021,39(25):3313-3314
23.
24.
《Vaccine》2020,38(36):5793-5802
Shingles is a painful, blistering rash caused by reactivation of latent varicella-zoster virus (VZV) and most frequently occurs in elderly and immunocompromised individuals. Currently, two approved vaccines for the prevention of shingles are on the market, a live attenuated virus vaccine ZOSTAVAX® (Merck & Co., Inc., Kenilworth, NJ, USA) and an AS01B adjuvanted subunit protein vaccine Shingrix™ (Glaxo Smith Kline, Rockville, MD, USA). Human clinical immunogenicity and vaccine efficacy data is available for these two benchmark vaccines, offering a unique opportunity for comparative analyses with novel vaccine platforms and animal model translatability studies.The studies presented here utilized non-human primates (NHP) to evaluate humoral and cellular immune response by three vaccine modalities: the new platform of lipid nanoparticle (LNP) formulated mRNA encoding VZV gE antigen (VZV gE mRNA/LNP) as compared with well-established platforms of live attenuated VZV (VZV LAV) and adjuvanted VZV gE subunit protein (VZV gE protein/adjuvant). The magnitude of response to vaccination with a single 100–200 μg mRNA dose or two 50 μg mRNA doses of VZV gE mRNA/LNP were comparable to two 50 μg protein doses of VZV gE protein/adjuvant, suggesting the VZV gE mRNA/LNP platform has the potential to elicit a robust immune response, and both modalities generated markedly higher responses than VZV LAV. Additionally, the slopes of decay for VZV-specific antibody titers were roughly similar across all three vaccines, indicating the magnitude of peak immunogenicity was the driving force in determining immune response longevity. Finally, vaccine-induced immunogenicity with VZV LAV and VZV gE protein/adjuvant in NHP closely resembled human clinical trials immune response data for ZOSTAVAX® and Shingrix™, helping to validate NHP as an appropriate preclinical model for evaluating these vaccines. 相似文献
25.
《The Egyptian Rheumatologist》2020,42(3):225-230
Aim of the workTo measure interleukin-33 (IL-33) serum and synovial fluid (SF) levels as well as its relative expression in peripheral blood mononuclear cells (PBMC) of juvenile idiopathic arthritis (JIA) patients and to study their relation to clinical, laboratory and musculoskeletal ultrasound characteristics, disease activity and functional status.Patients and methodsThe study included 60 JIA patients and 60 healthy controls and SF levels were measured in 20. Juvenile arthritis disease activity score (JADAS27) and Juvenile Arthritis Multidimensional Assessment Report (JAMAR) were assessed; Ten-joint grey scale (GS) and power Doppler (PD) MSUS score was performed. Rheumatoid factor (RF) titer and C-reactive protein (CRP) levels were measured.ResultsIn JIA patients, serum IL-33 levels (median 12.6; 7.4–23.8 ng/l) and its relative mRNA expression (median 3.3; 2.5–3.7) were significantly higher than their levels in the controls (median 1.7; 0.8–2.4 ng/l and median 1 ng/ml; p < 0.001). Polyarticular subtype (n = 20) had higher IL-33 serum levels compared to oligoarticular (n = 28, p < 0.001) and systemic-onset (n = 12, p = 0.006) subtypes. In JIA patients, the serum and SF levels of IL-33 significantly correlated with JADAS27 (p < 0.001 and 0.002 respectively), CRP (p < 0.001 and 0.007 respectively), GS (p < 0.001 and 0.001 respectively) and PD (p < 0.001 and 0.005 respectively). Serum IL-33 correlated with RF (p = 0.039) while, SF IL-33 correlated with physical function (p = 0.02).ConclusionsJIA patients have significantly elevated IL-33 serum concentrations and mRNA expression that considerably correlated with different inflammatory parameters, RF and physical function suggesting that it could be a valuable marker of JIA disease activity and implies a possible prognostic role. 相似文献
26.
27.
Dong Li Weihua Jiang Yiqun Jiang Shanshan Wang Junshun Fang Lihua Zhu 《Systems biology in reproductive medicine》2019,65(2):164-173
Long non-coding RNAs (lncRNAs), a class of non-coding RNA, have been shown to be essential in many diseases, such as infertility. Here, we found three candidate lncRNAs, ENST00000414116, ENST00000433673, and ENST00000448179, that are highly expressed in the uterus endometrial tissues of normal patients compared to the tissues of patients with adenomyosis, endometriosis, and recurrent implantation failure. lncRNAs ENST00000414116 and ENST00000433673 showed high expression in endometrial stromal cells (ESCs) and endometrial epithelial cells (EECs), respectively, and lncRNA ENST00000448179 was specifically expressed in ESCs. The bioinformatics analysis results indicated that the target mRNAs of lncRNA ENST00000433673 were related to biological adhesion. Interestingly, intercellular adhesion molecule 1 (ICAM1), an interacting mRNA of the target mRNA integrin subunit alpha L (ITGAL), has been reported be an important regulator of embryo implantation. Further studies found that the target mRNA ITGAL and the interacting mRNA ICAM1 were highly expressed in the uterus endometrial tissues and EECs of normal patients. Based on our results, our study indicates that lncRNA ENST00000433673 might mediate the high expression of the target mRNA ITGAL, thereby promoting the expression of the interacting mRNA ICAM1 and the adhesion of EECs, which facilitates adhesion and implantation between the embryo and the mater.
Abbreviations: AMs: adenomyosis; EMs: endometriosis; RIF: recurrent implantation failure; miRNAs: microRNAs; lncRNAs: Long non-coding RNAs; RT-qPCR: real-time quantitative PCR; ESCs: endometrial stromal cells; EECs: endometrial epithelial cells; BFE: free binding energy; PCDHB9: protocadherin beta 9; PARVG: parvin gamma; MAPK6: mitogen-activated protein kinase 6; LAF1: lymphocyte function-associated antigen 1 相似文献
28.
目的:通过构建肝细胞癌(hepatocellular carcinoma,HCC)的竞争性内源RNA(competing endogenous RNAs,ceRNA)调控网络,寻找与HCC发生发展及预后相关的分子。方法:从TCGA数据库下载HCC转录组数据,通过“Perl”语言处理转化得到mRNA、lncRNA和miRNA的表达谱矩阵。通过“Edge R”包提取3种RNA的差异表达基因(differential expression genes,DGEs),其阈值为|log FC|>2.0 且P<0.01。通过数据库比对得到差异lncRNA-差异miRNA、差异miRNA-差异mRNA关系对,导入至Cytoscape 软件构建ceRNA调控网络图。整理3 种DGEs相关的生存数据,通过“Survival”包及Kaplan-Meier Plotter 分析软件进行生存分析,绘制DGEs的生存曲线,分析获取预后相关基因。结果:成功构建HCC的lncRNA相关ceRNA调控网络,通过该网络分析DGEs 间的相互作用和调控关系,获取3 条lncRNA-miRNA-mRNA 调控关系对,其中1 条调控通路(CCDC26-hsa-mir-141-EPHA2)符合ceRNA 理论。预后分析显示,14 个mRNA高表达组患者生存率低于低表达组,可作为HCC不良预后的生物标志物;1 个lncRNA(TSPEAR-AS1)和2 个mRNA(CPEB3 和PROK2)低表达组患者生存率低于高表达组(P<0.05 或P<0.01),可能是HCC的保护性基因。结论:通过HCC lncRNA 相关的ceRNA调控网络筛查到高表达的14 个mRNA可能为HCC不良预后相关分子,低表达的1 个lncRNA和2 个mRNA可能为HCC良好预后相关分子,研究结果为HCC治疗和预后测评提供了参考依据。 相似文献
29.
《Vaccine》2021,39(51):7367-7374
We examined the impact of pre-existing SARS-CoV-2-specific cellular immunity on BNT162b2 mRNA COVID-19 vaccine reactogenicity. Of 96 healthcare workers (HCWs), 76% reported any vaccine reaction (first dose: 70%, second dose: 67%), none of which was severe. Following first dose, systemic reactions were significantly more frequent among HCWs with past infection than in infection-naïve individuals, and among HCWs with pre-existing cellular immunity than in those without it. The rate of systemic reactions after second dose was 1.7 and 2.0-times higher than after first dose among infection-naïve HCWs and those without pre-existing cellular immunity, respectively. Levels of SARS-CoV-2-specific T-cells before vaccination were higher in HCWs with systemic reactions after the first dose than in those without them. BNT162b2 vaccine reactogenicity after first dose is attributable to pre-existing cellular immunity elicited by prior COVID-19 or cross-reactivity. Reactogenicity following second dose suggests an immunity-boosting effect. Overall, these data may reduce negative attitudes towards COVID-19 vaccines.Study Registration.The study was registered on clinicaltrials.gov, NCT04402827. 相似文献
30.